Tirzepatide: a dual-action solution for obstructive sleep apnea and obesity.
作者信息
Afridi Zain, Farhan Kanza, Fahad Fnu, Khan Malik W Z, Salomon Izere
机构信息
Khyber Medical College, Peshawar, Pakistan.
Jinnah Sindh Medical University, Karachi, Pakistan.
出版信息
Ann Med Surg (Lond). 2024 Dec 12;87(2):436-437. doi: 10.1097/MS9.0000000000002975. eCollection 2025 Feb.
Abstract
摘要
相似文献
1
Tirzepatide: a dual-action solution for obstructive sleep apnea and obesity.替尔泊肽：治疗阻塞性睡眠呼吸暂停和肥胖症的双效解决方案。
Ann Med Surg (Lond). 2024 Dec 12;87(2):436-437. doi: 10.1097/MS9.0000000000002975. eCollection 2025 Feb.
2
Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials.评估替尔泊肽在睡眠呼吸暂停和肥胖中的心血管获益：来自 SURMOUNT-OSA 试验的见解。
Curr Obes Rep. 2024 Dec;13(4):739-742. doi: 10.1007/s13679-024-00592-x. Epub 2024 Oct 8.
3
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.替尔泊肽治疗阻塞性睡眠呼吸暂停和肥胖。
N Engl J Med. 2024 Oct 3;391(13):1193-1205. doi: 10.1056/NEJMoa2404881. Epub 2024 Jun 21.
4
[SURMOUNT-OSA study : tirzepatide improves obstructive sleep apnoea in patients with obesity].[SURMOUNT-OSA研究：替尔泊肽改善肥胖患者的阻塞性睡眠呼吸暂停]
Rev Med Liege. 2025 Apr;80(4):251-257.
5
Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial.特立帕肽治疗阻塞性睡眠呼吸暂停：SURMOUNT-OSA 三期临床试验的原理、设计和样本基线特征。
Contemp Clin Trials. 2024 Jun;141:107516. doi: 10.1016/j.cct.2024.107516. Epub 2024 Mar 26.
6
Exploring the Effects of Tirzepatide on Obstructive Sleep Apnea: A Literature Review.探索替尔泊肽对阻塞性睡眠呼吸暂停的影响：一项文献综述。
Cureus. 2025 Mar 6;17(3):e80164. doi: 10.7759/cureus.80164. eCollection 2025 Mar.
7
Clinical Impact of Tirzepatide on Patients With OSA and Obesity.替尔泊肽对阻塞性睡眠呼吸暂停和肥胖患者的临床影响。
Chest. 2025 Apr 18. doi: 10.1016/j.chest.2025.03.030.
8
[Tirzepatide : overview of clinical studies SURPASS in type 2 diabetes and SURMOUNT in obesity].[替尔泊肽：2型糖尿病的SURPASS和肥胖症的SURMOUNT临床研究概述]
Rev Med Liege. 2024 Dec;79(12):812-820.
9
What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?在阻塞性睡眠呼吸暂停（OSA）患者中使用替尔泊肽会有什么影响？
Sleep. 2025 Jun 13;48(6). doi: 10.1093/sleep/zsaf045.
10
[In patients with obesity and moderate to severe obstructive sleep apnea, is tirzepatide effective in reducing the apnea-hypopnea index compared to placebo, and is it safe?].在肥胖且患有中度至重度阻塞性睡眠呼吸暂停的患者中，与安慰剂相比，替尔泊肽在降低呼吸暂停低通气指数方面是否有效，以及它是否安全？
Rev Med Interne. 2025 Feb;46(2):124-125. doi: 10.1016/j.revmed.2024.12.002. Epub 2024 Dec 17.
本文引用的文献
1
The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist.替尔泊肽的心血管效应：一种胰高血糖素样肽-1和葡萄糖依赖性促胰岛素多肽双重激动剂
J Lipid Atheroscler. 2023 Sep;12(3):213-222. doi: 10.12997/jla.2023.12.3.213. Epub 2023 Jul 19.
2
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management.替尔泊肽在2型糖尿病和肥胖管理中的疗效与安全性。
J Obes Metab Syndr. 2023 Mar 30;32(1):25-45. doi: 10.7570/jomes22067. Epub 2023 Feb 8.
3
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.替尔泊肽，一种双重 GIP/GLP-1 受体激动剂，用于治疗 2 型糖尿病，在血糖控制和体重减轻方面具有无与伦比的疗效。
Cardiovasc Diabetol. 2022 Sep 1;21(1):169. doi: 10.1186/s12933-022-01604-7.
4
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.双重葡萄糖依赖性胰岛素促分泌多肽和胰高血糖素样肽-1 受体激动剂替西帕肽可改善 2 型糖尿病患者的心血管风险生物标志物：一项事后分析。
Diabetes Obes Metab. 2022 Jan;24(1):148-153. doi: 10.1111/dom.14553. Epub 2021 Oct 11.
5
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.替尔泊肽（双重GIP和GLP-1受体激动剂）在2型糖尿病管理中的作用：SURPASS临床试验
Diabetes Ther. 2021 Jan;12(1):143-157. doi: 10.1007/s13300-020-00981-0. Epub 2020 Dec 15.
6
Obstructive Sleep Apnea.阻塞性睡眠呼吸暂停。
Ann Intern Med. 2019 Dec 3;171(11):ITC81-ITC96. doi: 10.7326/AITC201912030.
7
Obstructive Sleep Apnea in Adults.成人阻塞性睡眠呼吸暂停
N Engl J Med. 2019 Apr 11;380(15):1442-1449. doi: 10.1056/NEJMcp1816152.
8
A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.一项关于口服缓释剂型苯丁胺/托吡酯治疗肥胖成年人阻塞性睡眠呼吸暂停的随机、双盲、安慰剂对照研究。
Sleep. 2012 Nov 1;35(11):1529-39. doi: 10.5665/sleep.2204.
Zotero 插件